# Janssen Scientific Affairs, LLC

Organization · id `cardio:org-janssen-scientific-affairs-llc` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Janssen+Scientific+Affairs%2C+LLC>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 8 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Janssen Scientific Affairs, LLC
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (`cardio:ct-nct01729871`)
- Sponsors: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (`cardio:ct-nct01830543`)
- Sponsors: Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents (`cardio:ct-nct01939496`)
- Sponsors: Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (`cardio:ct-nct02064439`)
- Sponsors: mHealth Screening to Prevent Strokes (`cardio:ct-nct02506244`)
- Sponsors: A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (`cardio:ct-nct02584660`)
- Sponsors: Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation (`cardio:ct-nct02996435`)
- Sponsors: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (`cardio:ct-nct05047172`)

## Provenance

Content hash: 2eac7d487a71df22e98f8a93e085bfa3c7ba8bfd33dfbe190bd2fb22919c0faf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
